Delivery Order SPE2DB20D3101-SPE2DB25FRQL2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,158.02 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and employs firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this delivery order under its larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,018.51 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a completion date of June 3, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $30.4K to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with an ultimate completion date of September 15, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a contract ceiling value of $52,267.14. This is a firm fixed-price delivery order with an ultimate completion date of September 30, 2025, and represents a non-competitive set-aside. The order will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,545.48 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, awarded on July 18, 2025, with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,937.05 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) injectable medication. The contract, awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency awarded a $53,875.27 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $65,172.95 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml injections. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025, and was awarded on September 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $43,056.67 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials. This firm fixed price contract, awarded on June 17, 2025, with an ultimate completion date of June 18, 2025, represents a non-competitive, non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $30,288.15 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRQL2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,984.57 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed-price, non-set-aside contract with a completion date of July 18, 2025, issued on July 17, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement across the Defense Health System. The company's substantial IDC vehicle enables the supply of a comprehensive range of pharmaceutical products, medical devices, and healthcare commodities to support military healthcare programs globally. This delivery order for Ozempic, a diabetes management medication, represents one of numerous competitive awards the vendor fulfills under its prime contract with DLA, demonstrating its capability to meet federal pharmaceutical supply requirements across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 7/17/25 |